Special Issue "Nanoparticles to Co-Deliver Immunopotentiators and Antigens"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (15 July 2016)
Prof. Dr. Olga Borges
Center for Neuroscience and Cell Biology & Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
Website 1 | Website 2 | E-Mail
Interests: focussed on the development of polymeric carriers as adjuvants for mucosal vaccination (protein and DNA) and examination of the interactions of delivery systems with biological targets in vitro and in vivo
Antigen delivery systems have primarily been used for protecting and gradually delivering antigens, achieving multimeric antigen presentation or simply mimicking the structure of virus. More recently, it has been reported that, in some cases, a direct effect on innate immune system cells is observed such as inflammasome activation, recognition by toll-like receptors, etc. Therefore, a depth and broad knowledge on the modes of action of the adjuvants will enable to better design nanoparticle-based adjuvants with predictable immune regulation. Since antigens should be close associated with adjuvants, a good strategy would be to construct nanoparticles that would be able to co-delivery immunopotentiators and recombinant antigens. Nanoparticles can have inherent immunopotentiator effect, so, the association or encapsulation of a second immunopotentiator will allow to better modulating the immune response, allowing different applications like the development of immunotherapies, or vaccines for chronic diseases.
This special issue of vaccines will cover topics close related with the emerging approaches in immunobioengineering with specific focus on considerations related with the rationale behind the design of an antigen delivery system, including, besides the recombinant antigen, the encapsulation of substances with immunopotentiator effect or for example the link of molecules that would be recognized by antigen presenting cell surface receptors.
Assist. Prof. Olga Borges
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 650 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vaccine adjuvants
- modulation of the immune response
- Adjuvant mechanistic studies